Mylan announced the launch of Methocarbamol Injection, the generic version of Hikma Maple’s Robaxin Injection.
Robaxin is approved as adjunct therapy for the relief of discomfort associated with acute, painful musculoskeletal conditions, in combination with rest, physical therapy, and other measures. Its mechanism of action has not been established, but may be due to general CNS depression with sedative and musculoskeletal relaxant properties.
Methocarbamol Injection is available as a 100mg/mL strength in 10mL single-dose vials. Mylan has begun shipping this product.
For more information call (800) RX-MYLAN or visit Mylan.com.